8 31/03/2024 2024-03-31 false false false false false false false true false false true false false false false false false false No description of principal activities is disclosed 2023-04-01 Sage Accounts Production 23.0 - FRS102_2021 xbrli:pure xbrli:shares iso4217:GBP NI069302 2023-04-01 2024-03-31 NI069302 2024-03-31 NI069302 2023-03-31 NI069302 2022-04-01 2023-03-31 NI069302 2023-03-31 NI069302 2022-03-31 NI069302 bus:RegisteredOffice 2023-04-01 2024-03-31 NI069302 bus:LeadAgentIfApplicable 2023-04-01 2024-03-31 NI069302 bus:Director1 2023-04-01 2024-03-31 NI069302 bus:Director2 2023-04-01 2024-03-31 NI069302 bus:Director3 2023-04-01 2024-03-31 NI069302 bus:CompanySecretary1 2023-04-01 2024-03-31 NI069302 core:NetGoodwill 2024-03-31 NI069302 core:FurnitureFittingsToolsEquipment 2023-03-31 NI069302 core:FurnitureFittingsToolsEquipment 2024-03-31 NI069302 core:WithinOneYear 2024-03-31 NI069302 core:WithinOneYear 2023-03-31 NI069302 core:RetainedEarningsAccumulatedLosses 2022-04-01 2023-03-31 NI069302 core:RetainedEarningsAccumulatedLosses 2023-04-01 2024-03-31 NI069302 core:ShareCapital 2024-03-31 NI069302 core:ShareCapital 2023-03-31 NI069302 core:RetainedEarningsAccumulatedLosses 2024-03-31 NI069302 core:RetainedEarningsAccumulatedLosses 2023-03-31 NI069302 core:ShareCapital 2022-03-31 NI069302 core:RetainedEarningsAccumulatedLosses 2022-03-31 NI069302 core:FurnitureFittingsToolsEquipment 2023-04-01 2024-03-31 NI069302 core:NetGoodwill 2023-03-31 NI069302 core:FurnitureFittingsToolsEquipment 2023-03-31 NI069302 bus:SmallEntities 2023-04-01 2024-03-31 NI069302 bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-31 NI069302 bus:FullAccounts 2023-04-01 2024-03-31 NI069302 bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 NI069302 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31
Company registration number: NI069302
Bovally Pharmacy Ltd
Unaudited filleted financial statements
31 March 2024
Bovally Pharmacy Ltd
Contents
Directors and other information
Accountants report
Statement of financial position
Statement of changes in equity
Notes to the financial statements
Bovally Pharmacy Ltd
Directors and other information
Directors Mr Brendan Gormley
Mr David Gibson
Mr Samuel Wilkinson
Secretary Brendan Gormley
Company number NI069302
Registered office 8 Anderson Avenue
Limavady
Co Derry
BT49 0TF
Accountants PFS Accountants & Auditors Ltd
122 Main Street
Chartered Certified Accountants
Dungiven
Co Derry
BT47 4LG
Bankers Danske Bank
46 Catherine Street
Limavady
Co Derry
BT49 9DH
Bovally Pharmacy Ltd
Report to the board of directors on the preparation of the
unaudited statutory financial statements of Bovally Pharmacy Ltd
Year ended 31 March 2024
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Bovally Pharmacy Ltd for the year ended 31 March 2024 which comprise the statement of financial position, statement of changes in equity and related notes from the company's accounting records and from information and explanations you have given us.
As a practising member firm of the Association of Chartered Certified Accountants , we are subject to its ethical and other professional requirements which are detailed at http://www.accaglobal.com/en/member/ professional-standards/ rules-standards/acca-rulebook.html.
This report is made solely to the board of directors of Bovally Pharmacy Ltd, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of Bovally Pharmacy Ltd and state those matters that we have agreed to state to the board of directors of Bovally Pharmacy Ltd as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/content/dam/ACCA_Global /Technical/fact/technical-factsheet-163.pdf. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Bovally Pharmacy Ltd and its board of directors as a body for our work or for this report.
It is your duty to ensure that Bovally Pharmacy Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Bovally Pharmacy Ltd. You consider that Bovally Pharmacy Ltd is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the financial statements of Bovally Pharmacy Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.
PFS Accountants & Auditors Ltd
Chartered Certified Accountants
122 Main Street
Dungiven
Co Derry
BT47 4LG
18 October 2024
Bovally Pharmacy Ltd
Statement of financial position
31 March 2024
2024 2023
Note £ £ £ £
Fixed assets
Intangible assets 5 - -
Tangible assets 6 1,633 2,805
_______ _______
1,633 2,805
Current assets
Stocks 52,576 47,354
Debtors 7 123,219 125,821
Cash at bank and in hand 165,501 191,630
_______ _______
341,296 364,805
Creditors: amounts falling due
within one year 8 ( 186,595) ( 204,376)
_______ _______
Net current assets 154,701 160,429
_______ _______
Total assets less current liabilities 156,334 163,234
Provisions for liabilities ( 310) ( 561)
_______ _______
Net assets 156,024 162,673
_______ _______
Capital and reserves
Called up share capital 99 99
Profit and loss account 155,925 162,574
_______ _______
Shareholders funds 156,024 162,673
_______ _______
For the year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the income statement has not been delivered.
These financial statements were approved by the board of directors and authorised for issue on 18 October 2024 , and are signed on behalf of the board by:
Mr Brendan Gormley
Director
Company registration number: NI069302
Bovally Pharmacy Ltd
Statement of changes in equity
Year ended 31 March 2024
Called up share capital Profit and loss account Total
£ £ £
At 1 April 2022 99 196,755 196,854
Profit for the year 25,819 25,819
_______ _______ _______
Total comprehensive income for the year - 25,819 25,819
Dividends paid and payable ( 60,000) ( 60,000)
_______ _______ _______
Total investments by and distributions to owners - ( 60,000) ( 60,000)
_______ _______ _______
At 31 March 2023 and 1 April 2023 99 162,574 162,673
Profit for the year 38,351 38,351
_______ _______ _______
Total comprehensive income for the year - 38,351 38,351
Dividends paid and payable ( 45,000) ( 45,000)
_______ _______ _______
Total investments by and distributions to owners - ( 45,000) ( 45,000)
_______ _______ _______
At 31 March 2024 99 155,925 156,024
_______ _______ _______
Bovally Pharmacy Ltd
Notes to the financial statements
Year ended 31 March 2024
1. General information
The company is a private company limited by shares, registered in Northern Ireland. The address of the registered office is 8 Anderson Avenue, Limavady, Co Derry, BT49 0TF.
2. Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Turnover
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Amortisation
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:
If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.
Tangible assets
tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.
Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.
Provisions
Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event; it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense. Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset. When a provision is measured at the present value of the amount expected to be required to settle the obligation, the unwinding of the discount is recognised in finance costs in profit or loss in the period it arises.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
Defined contribution plans
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised in finance costs in profit or loss in the period in which it arises.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 8 (2023: 9 ).
5. Intangible assets
Goodwill Total
£ £
Cost
At 1 April 2023 and 31 March 2024 863,032 863,032
_______ _______
Amortisation
At 1 April 2023 and 31 March 2024 863,032 863,032
_______ _______
Carrying amount
At 31 March 2024 - -
_______ _______
At 31 March 2023 - -
_______ _______
6. Tangible assets
Fixtures, fittings and equipment Total
£ £
Cost
At 1 April 2023 and 31 March 2024 12,720 12,720
_______ _______
Depreciation
At 1 April 2023 9,915 9,915
Charge for the year 1,172 1,172
_______ _______
At 31 March 2024 11,087 11,087
_______ _______
Carrying amount
At 31 March 2024 1,633 1,633
_______ _______
At 31 March 2023 2,805 2,805
_______ _______
7. Debtors
2024 2023
£ £
Trade debtors 88,577 83,257
Other debtors 34,642 42,564
_______ _______
123,219 125,821
_______ _______
8. Creditors: amounts falling due within one year
2024 2023
£ £
Bank loans and overdrafts - 15,000
Trade creditors 168,653 139,044
Corporation tax 9,212 6,211
Social security and other taxes 5,192 4,711
Other creditors 3,538 39,410
_______ _______
186,595 204,376
_______ _______